Current insights into the treatments of severe aplastic anemia in China
Recently, several studies have been conducted to generate considerable evidence regarding unique treatments for severe aplastic anemia (SAA) in China. Haploidentical donor hematopoietic stem cell transplantation (HID-HSCT) showed an overall survival rate (80.3–86.1%) comparable to those with immunos...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2020-09, Vol.112 (3), p.292-299 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 299 |
|---|---|
| container_issue | 3 |
| container_start_page | 292 |
| container_title | International journal of hematology |
| container_volume | 112 |
| creator | Ye, Lei Zhang, Fengkui Kojima, Seiji |
| description | Recently, several studies have been conducted to generate considerable evidence regarding unique treatments for severe aplastic anemia (SAA) in China. Haploidentical donor hematopoietic stem cell transplantation (HID-HSCT) showed an overall survival rate (80.3–86.1%) comparable to those with immunosuppressive therapy (IST) and matched related donor (MRD)- and matched unrelated donor (MUD)-HSCT. Failure-free survival of HID-HSCT was also comparable (76.4–85.0%) to those of MRD- and MUD-HSCT and better than IST in patients |
| doi_str_mv | 10.1007/s12185-020-02955-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2430368765</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2437639178</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-de2e2cc46877faded62debef469dbfb9a76e6c17d187dde999e9773b0fa85cc13</originalsourceid><addsrcrecordid>eNp9kEtLBDEQhIMouK7-AU8BL15G85gkk6MsugqCFz2HTNKzO8s81iQj-O_NOoLgwUPTDf1VURRCl5TcUELUbaSMVqIgjOTRQhT0CC1oJUXBlSqP0YJoJgqhKDlFZzHuCKGKlGqB1qspBBgSbofYbrYp5iONOG0BpwA29fkX8djgCB8QANt9Z2NqHbYD9K3NNF5t28Geo5PGdhEufvYSvT3cv64ei-eX9dPq7rlwXMlUeGDAnCtlpVRjPXjJPNTQlFL7uqm1VRKko8rTSnkPWmvQSvGaNLYSzlG-RNez7z6M7xPEZPo2Oui6nGecomElJzy7S5HRqz_obpzCkNMdKCW5pqrKFJspF8YYAzRmH9rehk9DiTl0a-ZuTe7WfHdrDin4LIoZHjYQfq3_UX0BGEt8-A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2437639178</pqid></control><display><type>article</type><title>Current insights into the treatments of severe aplastic anemia in China</title><source>SpringerLink Journals (MCLS)</source><creator>Ye, Lei ; Zhang, Fengkui ; Kojima, Seiji</creator><creatorcontrib>Ye, Lei ; Zhang, Fengkui ; Kojima, Seiji</creatorcontrib><description>Recently, several studies have been conducted to generate considerable evidence regarding unique treatments for severe aplastic anemia (SAA) in China. Haploidentical donor hematopoietic stem cell transplantation (HID-HSCT) showed an overall survival rate (80.3–86.1%) comparable to those with immunosuppressive therapy (IST) and matched related donor (MRD)- and matched unrelated donor (MUD)-HSCT. Failure-free survival of HID-HSCT was also comparable (76.4–85.0%) to those of MRD- and MUD-HSCT and better than IST in patients < 40 years. Although these results are promising, HID-HSCT should be regarded as a salvage therapy when young patients fail to respond to IST. Porcine anti-human lymphocyte immunoglobulin (pALG) showed similar or superior overall response at 6 months compared to rabbit anti-human thymocyte immunoglobulin (rATG) (64.0–79.4% in the pALG-group vs.48.1–64.7% in the rATG-group) as a first-line IST. Promising hematological response (28.4–33.3%) was observed in patients with refractory AA following infusion of the mesenchymal stromal cells (MSCs) derived from the bone marrow of allogeneic donors. pALG can replace rATG as an immunosuppressive drug and MSCs infusion can be used as a second-line treatment for refractory SAA. We believe that this review contributes to refine the global practices for SAA treatment.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-020-02955-1</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Anemia ; Aplastic anemia ; Bone marrow ; Bone marrow transplantation ; Hematology ; Hematopoietic stem cells ; Immunoglobulins ; Immunosuppressive agents ; Lymphocytes ; Medicine ; Medicine & Public Health ; Mesenchymal stem cells ; Mesenchyme ; Mud ; Oncology ; Review Article ; Stem cell transplantation ; Stem cells ; Stromal cells ; Survival ; Transplantation</subject><ispartof>International journal of hematology, 2020-09, Vol.112 (3), p.292-299</ispartof><rights>Japanese Society of Hematology 2020</rights><rights>Japanese Society of Hematology 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c376t-de2e2cc46877faded62debef469dbfb9a76e6c17d187dde999e9773b0fa85cc13</citedby><cites>FETCH-LOGICAL-c376t-de2e2cc46877faded62debef469dbfb9a76e6c17d187dde999e9773b0fa85cc13</cites><orcidid>0000-0001-8643-2987</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-020-02955-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-020-02955-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Ye, Lei</creatorcontrib><creatorcontrib>Zhang, Fengkui</creatorcontrib><creatorcontrib>Kojima, Seiji</creatorcontrib><title>Current insights into the treatments of severe aplastic anemia in China</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><description>Recently, several studies have been conducted to generate considerable evidence regarding unique treatments for severe aplastic anemia (SAA) in China. Haploidentical donor hematopoietic stem cell transplantation (HID-HSCT) showed an overall survival rate (80.3–86.1%) comparable to those with immunosuppressive therapy (IST) and matched related donor (MRD)- and matched unrelated donor (MUD)-HSCT. Failure-free survival of HID-HSCT was also comparable (76.4–85.0%) to those of MRD- and MUD-HSCT and better than IST in patients < 40 years. Although these results are promising, HID-HSCT should be regarded as a salvage therapy when young patients fail to respond to IST. Porcine anti-human lymphocyte immunoglobulin (pALG) showed similar or superior overall response at 6 months compared to rabbit anti-human thymocyte immunoglobulin (rATG) (64.0–79.4% in the pALG-group vs.48.1–64.7% in the rATG-group) as a first-line IST. Promising hematological response (28.4–33.3%) was observed in patients with refractory AA following infusion of the mesenchymal stromal cells (MSCs) derived from the bone marrow of allogeneic donors. pALG can replace rATG as an immunosuppressive drug and MSCs infusion can be used as a second-line treatment for refractory SAA. We believe that this review contributes to refine the global practices for SAA treatment.</description><subject>Anemia</subject><subject>Aplastic anemia</subject><subject>Bone marrow</subject><subject>Bone marrow transplantation</subject><subject>Hematology</subject><subject>Hematopoietic stem cells</subject><subject>Immunoglobulins</subject><subject>Immunosuppressive agents</subject><subject>Lymphocytes</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mesenchymal stem cells</subject><subject>Mesenchyme</subject><subject>Mud</subject><subject>Oncology</subject><subject>Review Article</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Stromal cells</subject><subject>Survival</subject><subject>Transplantation</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kEtLBDEQhIMouK7-AU8BL15G85gkk6MsugqCFz2HTNKzO8s81iQj-O_NOoLgwUPTDf1VURRCl5TcUELUbaSMVqIgjOTRQhT0CC1oJUXBlSqP0YJoJgqhKDlFZzHuCKGKlGqB1qspBBgSbofYbrYp5iONOG0BpwA29fkX8djgCB8QANt9Z2NqHbYD9K3NNF5t28Geo5PGdhEufvYSvT3cv64ei-eX9dPq7rlwXMlUeGDAnCtlpVRjPXjJPNTQlFL7uqm1VRKko8rTSnkPWmvQSvGaNLYSzlG-RNez7z6M7xPEZPo2Oui6nGecomElJzy7S5HRqz_obpzCkNMdKCW5pqrKFJspF8YYAzRmH9rehk9DiTl0a-ZuTe7WfHdrDin4LIoZHjYQfq3_UX0BGEt8-A</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Ye, Lei</creator><creator>Zhang, Fengkui</creator><creator>Kojima, Seiji</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8643-2987</orcidid></search><sort><creationdate>20200901</creationdate><title>Current insights into the treatments of severe aplastic anemia in China</title><author>Ye, Lei ; Zhang, Fengkui ; Kojima, Seiji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-de2e2cc46877faded62debef469dbfb9a76e6c17d187dde999e9773b0fa85cc13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Anemia</topic><topic>Aplastic anemia</topic><topic>Bone marrow</topic><topic>Bone marrow transplantation</topic><topic>Hematology</topic><topic>Hematopoietic stem cells</topic><topic>Immunoglobulins</topic><topic>Immunosuppressive agents</topic><topic>Lymphocytes</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mesenchymal stem cells</topic><topic>Mesenchyme</topic><topic>Mud</topic><topic>Oncology</topic><topic>Review Article</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Stromal cells</topic><topic>Survival</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ye, Lei</creatorcontrib><creatorcontrib>Zhang, Fengkui</creatorcontrib><creatorcontrib>Kojima, Seiji</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ye, Lei</au><au>Zhang, Fengkui</au><au>Kojima, Seiji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current insights into the treatments of severe aplastic anemia in China</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><date>2020-09-01</date><risdate>2020</risdate><volume>112</volume><issue>3</issue><spage>292</spage><epage>299</epage><pages>292-299</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Recently, several studies have been conducted to generate considerable evidence regarding unique treatments for severe aplastic anemia (SAA) in China. Haploidentical donor hematopoietic stem cell transplantation (HID-HSCT) showed an overall survival rate (80.3–86.1%) comparable to those with immunosuppressive therapy (IST) and matched related donor (MRD)- and matched unrelated donor (MUD)-HSCT. Failure-free survival of HID-HSCT was also comparable (76.4–85.0%) to those of MRD- and MUD-HSCT and better than IST in patients < 40 years. Although these results are promising, HID-HSCT should be regarded as a salvage therapy when young patients fail to respond to IST. Porcine anti-human lymphocyte immunoglobulin (pALG) showed similar or superior overall response at 6 months compared to rabbit anti-human thymocyte immunoglobulin (rATG) (64.0–79.4% in the pALG-group vs.48.1–64.7% in the rATG-group) as a first-line IST. Promising hematological response (28.4–33.3%) was observed in patients with refractory AA following infusion of the mesenchymal stromal cells (MSCs) derived from the bone marrow of allogeneic donors. pALG can replace rATG as an immunosuppressive drug and MSCs infusion can be used as a second-line treatment for refractory SAA. We believe that this review contributes to refine the global practices for SAA treatment.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><doi>10.1007/s12185-020-02955-1</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-8643-2987</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2020-09, Vol.112 (3), p.292-299 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2430368765 |
| source | SpringerLink Journals (MCLS) |
| subjects | Anemia Aplastic anemia Bone marrow Bone marrow transplantation Hematology Hematopoietic stem cells Immunoglobulins Immunosuppressive agents Lymphocytes Medicine Medicine & Public Health Mesenchymal stem cells Mesenchyme Mud Oncology Review Article Stem cell transplantation Stem cells Stromal cells Survival Transplantation |
| title | Current insights into the treatments of severe aplastic anemia in China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T02%3A27%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20insights%20into%20the%20treatments%20of%20severe%20aplastic%20anemia%20in%20China&rft.jtitle=International%20journal%20of%20hematology&rft.au=Ye,%20Lei&rft.date=2020-09-01&rft.volume=112&rft.issue=3&rft.spage=292&rft.epage=299&rft.pages=292-299&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-020-02955-1&rft_dat=%3Cproquest_cross%3E2437639178%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2437639178&rft_id=info:pmid/&rfr_iscdi=true |